Biotechnology Gets Shot in the Arm
Sydney Williams submits:
Yesterday’s passage of comprehensive health reform no doubt opens a Pandora’s box. And while legal challenges may eventually block its full implementation, an outright repeal is unlikely, which means many—if not most—provisions will remain in effect.
One such provision is the creation of a pathway for follow-on biologics ("FOBs", or generic biologics)—new versions of innovator products. For years, the industry has been at an impasse over data exclusivity and patent law.
Investing, Long Term Investment, stock market | admin March 22, 2010
RSS feed for comments on this post.
